We are a pre-clinical drug development company focused on novel therapies to target cancer, with specific focus on kidney cancer.
Our mission is to create a new paradigm for the treatment of cancer, through the induction of ferroptosis.
We have developed a revolutionary small molecule with a dual mechanism of action of blocking the tumor driver, hypoxia-inducible factor (HIF)-2α and inducing cell death through excessive iron accumulation (ferroptosis).
The combination of ferroptosis induction + HIF-2α inhibition is a game-changing cancer treatment strategy with promising anti-tumor activity in animal models.
In 2018, Kuda Therapeutics was awarded a $300,000 SBIR Phase 1 grant from the National Cancer Institute to develop its novel anti-cancer therapeutics.
In 2020, Kuda Therapeutics received a $560,000 Idea Award from the Department of Defense to advance its ferroptosis inducer technology.
In 2022, Kuda Therapeutics was awarded a $2,050,000 SBIR Phase II grant from the National Cancer Institute to advance this technology towards FDA Investigational New Drug (IND) filing for human proof-of-concept studies.
In 2024, Kuda Therapeutics was awarded a $420,000 Award from the Department Defense to investigate the utility of this revolutionary approach for the treatment of ovarian cancer.